BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

1. Santamaría, C.
2. Chillón, M.C.
3. García-Sanz, R.
4. Pérez, C.
5. Caballero, M.D.
6. Mateos, M.V.
7. Ramos, F.
8. De Coca, A.G.
9. Alonso, J.M.
10. Giraldo, P.
11. Bernal, T.
12. Queizán, J.A.
13. Rodríguez, J.N.
14. Puig, N.
15. Balanzategui, A.
16. Sarasquete, M.E.
17. Alcoceba, M.
18. Díaz-Mediavilla, J.
19. San Miguel, J.
20. González, M.